Regeneron Clinical Trials: 396 Led Studies

Archive historyOct 2022 to Jun 2026

115 recorded changes across Regeneron trials

Every status move, completion date shift and enrollment change ComplyRx has recorded across 37 of these trials. One is shown below.

Completion date movePrimary completion moved 114 days laterNCT06572228 · recorded 1 Jun 2026

Track to read them

+111 more recorded changes · Track a drug to see every change the night it lands

Track dupilumab

Most active programmes

The drugs appearing most often across Regeneron's recently active trials. Comparator arms are excluded.

Cemiplimab11 trials
REGN750810 trials
Linvoseltamab10 trials
Dupilumab7 trials
cemiplimab6 trials
Odronextamab6 trials

Upcoming readouts

Next primary completion dates among Regeneron's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.

Dec 2026ASCEND-QW: A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who …Phase 2
Feb 2027ROXI-ATLAS: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationPhase 2
Feb 2027ROXI-APEX: REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in …Phase 3
Feb 2027Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch P…Phase 3
Mar 2027A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Adva…Phase 3
May 2027ROXI-ASPEN: REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthro…Phase 3

Top therapeutic areas

Conditions studied most often across Regeneron's recently active trials.

Melanoma4 trials
Non-small Cell Lung Cancer3 trials
Venous Thromboembolism (VTE)3 trials
Atrial Fibrillation (AF)3 trials
Overweight or Obesity3 trials
Allergic Conjunctivitis3 trials

Regeneron trials

The 50 most significant of Regeneron's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.

Trial	Phase	Stability	Status	Enrollment	Est. readout
A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With SurgeryNCT05608291Fianlimab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	1,564 est.	27 Jul 2026
Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)NCT02612454Dupilumab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	880 est.	7 Oct 2026
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the USNCT07431086Olatorepatide	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	120 est.	13 Nov 2026
COMBINE-EGFR-1A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced CancersNCT04626635REGN7075	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	548 est.	13 Nov 2026
FERVENT-1A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the BodyNCT06421636REGN7999	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	19 est.	3 Dec 2026
ASCEND-QWA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have HypercholesterolemiaNCT07477704Alirocumab	Phase 2	Locked · track to reveal	OngoingRecruiting	420 est.	29 Dec 2026
ROXI-ATLASSafety in Adult Participants With Atrial Fibrillation Who Are Treated With AnticoagulationNCT07175428REGN7508	Phase 2	Locked · track to reveal	OngoingRecruiting	1,200 est.	9 Feb 2027
ROXI-APEXREGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in AdultsNCT07015905REGN7508	Phase 3	Locked · track to reveal	OngoingRecruiting	2,000 est.	20 Feb 2027
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or ObesityNCT07594093REGN20934	Phase 1	Locked · track to reveal	OngoingRecruiting	90 est.	22 Feb 2027
Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen AllergyNCT07309432REGN5713	Phase 3	Locked · track to reveal	OngoingRecruiting	350 est.	28 Feb 2027
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)NCT06246916fianlimab	Phase 3	Locked · track to reveal	OngoingRecruiting	560 est.	22 Mar 2027
AROMAStudy Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)NCT04959448DUPIXENT®	—	Locked · track to reveal	OngoingActive, not recruiting	717 est.	25 Mar 2027
Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) PatientsNCT06269133REGN2810	—	Not yet scored	OngoingActive, not recruiting	1,000 est.	31 Mar 2027
AIM4:Next StepEfficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled AsthmaNCT06572228dupilumab	Phase 4	Locked · track to reveal	OngoingActive, not recruiting	120 est.	24 Apr 2027
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) CancersNCT03564340Ubamatamab	Phase 1	Locked · track to reveal	OngoingRecruiting	890 est.	10 May 2027
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)NCT06836609ALN-CIDEB	Phase 1	Locked · track to reveal	OngoingRecruiting	132 est.	15 May 2027
ROXI-ASPENREGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult ParticipantsNCT07213778REGN7508	Phase 3	Locked · track to reveal	OngoingRecruiting	2,000 est.	17 May 2027
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)NCT06465329Cemiplimab	Phase 2	Locked · track to reveal	OngoingRecruiting	120 est.	20 May 2027
An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney TransplantNCT05106387Noninterventional	—	Not yet scored	OngoingRecruiting	20 est.	14 Jun 2027
KYRIADA Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic AmenorrheaNCT07235917Mibavademab	Phase 2	Locked · track to reveal	OngoingRecruiting	34 est.	20 Aug 2027
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food AllergyNCT06369467linvoseltamab	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	6 est.	31 Aug 2027
ANCHOR-POCStudy to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney DiseaseNCT07271186ALN-ANG3	Phase 2	Locked · track to reveal	OngoingRecruiting	270 est.	24 Sept 2027
A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)NCT05785767fianlimab	Phase 2	Locked · track to reveal	OngoingActive, not recruiting	149 est.	28 Sept 2027
POPLINAdult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS)NCT07609940Linvoseltamab	Phase 4	Locked · track to reveal	OngoingNot yet recruiting	30 est.	11 Oct 2027
A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat AllergyNCT07675811REGN-2Cat	Phase 3	Not yet scored	OngoingNot yet recruiting	570 est.	16 Oct 2027
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other TumorsNCT03972657REGN5678	Phase 1	Locked · track to reveal	OngoingRecruiting	345 est.	15 Nov 2027
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)NCT05092347Vonsetamig	Phase 1	Locked · track to reveal	OngoingActive, not recruiting	43 est.	22 Nov 2027
SIENNAA Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic AtrophyNCT06541704Pozelimab	Phase 3	Locked · track to reveal	OngoingRecruiting	975 est.	29 Nov 2027
A Study to Identify and Characterize Adults and Pediatric Participants With Cat and/or Birch AllergyNCT07710846Noninterventional	—	Not yet scored	OngoingNot yet recruiting	1,500 est.	10 Jan 2028
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without DiabetesNCT07685808Olatorepatide	Phase 2	Not yet scored	OngoingNot yet recruiting	360 est.	21 Jan 2028
OLYMPIA-1A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular LymphomaNCT06091254Odronextamab	Phase 3	Locked · track to reveal	OngoingRecruiting	822 est.	7 Feb 2028
ILLUMINATEStudy of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)NCT07318597REGN13335	Phase 2	Locked · track to reveal	OngoingRecruiting	99 est.	27 Feb 2028
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care TreatmentsNCT05137054Linvoseltamab	Phase 1	Locked · track to reveal	OngoingRecruiting	317 est.	25 Mar 2028
OLYMPIA-3A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell LymphomaNCT06091865Odronextamab	Phase 3	Locked · track to reveal	OngoingRecruiting	904 est.	30 Mar 2028
NASHGEN-2A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This ConditionNCT05519475ALN-HSD	Phase 2	Locked · track to reveal	OngoingRecruiting	120 est.	27 Apr 2028
LAGOEfficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized LipodystrophyNCT07220785Mibavademab	Phase 3	Locked · track to reveal	OngoingRecruiting	28 est.	19 May 2028
OLYMPIA-4A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin LymphomaNCT06230224Odronextamab	Phase 3	Locked · track to reveal	OngoingActive, not recruiting	216 est.	29 May 2028
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNCT06769698FDC fianlimab+cemiplimab	Phase 2	Locked · track to reveal	OngoingRecruiting	120 est.	4 Jun 2028
EoE-TOTsA Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic EsophagitisNCT07112378dupilumab	Phase 3	Locked · track to reveal	OngoingRecruiting	20 est.	19 Jun 2028
AURA-ADFirst-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic DermatitisNCT07527923REGN20423	Phase 1	Locked · track to reveal	OngoingRecruiting	144 est.	23 Jun 2028
VIENNAIntravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult ParticipantsNCT07230834Pozelimab	Phase 1	Locked · track to reveal	OngoingRecruiting	54 est.	3 Jul 2028
MISSIONThis After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring HospitalizationNCT07587658dupilumab	Phase 4	Locked · track to reveal	OngoingNot yet recruiting	754 est.	30 Jul 2028
LINKER-AL2A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)NCT06292780Linvoseltamab	Phase 1	Locked · track to reveal	OngoingRecruiting	220 est.	20 Aug 2028
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian CancerNCT06787612Ubamatamab	Phase 2	Locked · track to reveal	OngoingRecruiting	220 est.	30 Oct 2028
CEMI-LUNGAn Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNCT05363319Cemiplimab	—	Not yet scored	OngoingRecruiting	500 est.	30 Oct 2028
OLYMPIA-5A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaNCT06149286Odronextamab	Phase 3	Locked · track to reveal	OngoingRecruiting	470 est.	23 Jan 2029
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)NCT07631637ALN-CIDEB	Phase 2	Not yet scored	OngoingNot yet recruiting	150 est.	6 Feb 2029
ATHENA-1A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin LymphomasNCT05685173Odronextamab	Phase 1	Locked · track to reveal	OngoingRecruiting	107 est.	16 Feb 2029
ACCESS-EXTA Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it WorksNCT05744921Pozelimab	Phase 3	Locked · track to reveal	OngoingRecruiting	202 est.	26 Feb 2029
CHORDA Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin MutationsNCT05788536DB-OTO	Phase 1	Locked · track to reveal	OngoingRecruiting	36 est.	26 Feb 2029

View all trials396

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

Phase 3Active, not recruitingNCT05608291 ↗

Primary completion: Jul 2026; estimated
Enrollment: 1,564; estimated
Start: Jan 2023; Regeneron Pharmaceuticals

Conditions

Melanoma

Interventions

Fianlimab
Cemiplimab
Pembrolizumab
Placebo

Brief summary

This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called cemiplimab (each individually called a "study drug" or called "study drugs" when combined) compared with an approved medication called pembrolizumab. The objective of this…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jul 2025

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Phase 3Active, not recruitingNCT02612454 ↗

Primary completion: Oct 2026; estimated
Enrollment: 880; estimated
Start: Oct 2015; Regeneron Pharmaceuticals

Conditions

Atopic Dermatitis

Interventions

Dupilumab

Brief summary

The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD. The secondary objectives of the study are: * To assess the long-term efficacy of dupilumab in pediatric participants with AD * To assess the trough concentrations of functional dupilumab in serum and…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jul 2024

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US

Phase 2Active, not recruitingNCT07431086 ↗

Primary completion: Nov 2026; estimated
Enrollment: 120; estimated
Start: Mar 2026; Regeneron Pharmaceuticals

Conditions

Overweight or Obesity

Interventions

Olatorepatide
Placebo

Brief summary

This study will test olatorepatide (study drug) to determine how safe and effective this drug is and how easily your body can accept this drug without causing side effects, as well as how the drug is processed in the body by participants with overweight or obesity. The study will test how safe and effective the study…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

COMBINE-EGFR-1: A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers

Phase 1Active, not recruitingNCT04626635 ↗

Primary completion: Nov 2026; estimated
Enrollment: 548; estimated
Start: Dec 2020; Regeneron Pharmaceuticals

Conditions

Advanced Solid Tumors

Interventions

REGN7075
Cemiplimab
Platinum-based doublet chemotherapy
Bevacizumab
Trifluridine-tipiracil

Brief summary

This study is researching an investigational drug called marlotamig (REGN7075) by itself and in combination with cemiplimab with or without chemotherapy. The study is focused on patients with certain solid tumors that are in an advanced stage. The aim of the study is to see how safe and tolerable marlotamig is by…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jan 2025

Enrollment change · 2

Completion date move · 2

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

FERVENT-1: A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body

Phase 2Active, not recruitingNCT06421636 ↗

Primary completion: Dec 2026; estimated
Enrollment: 19; estimated
Start: Sept 2024; Regeneron Pharmaceuticals

Conditions

Non-Transfusion Dependent Beta-Thalassemia (NTDT)

Interventions

REGN7999
Placebo

Brief summary

This study is researching an experimental drug called REGN7999 (called "study drug"). The study is focused on patients with non-transfusion dependent beta-thalassemia. The aim of the study is to see how safe and effective the study drug is. The study is looking at several other research questions, including: *…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Jan 2025

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

ROXI-ATLAS: Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

Phase 2RecruitingNCT07175428 ↗

Primary completion: Feb 2027; estimated
Enrollment: 1,200; estimated
Start: Oct 2025; Regeneron Pharmaceuticals

Conditions

Atrial Fibrillation (AF)

Interventions

REGN7508
REGN9933
Apixaban

Brief summary

This study is researching experimental drugs called REGN7508 and REGN9933. The study is focused on participants who have atrial fibrillation, which means that the heart beats too fast and unevenly. REGN7508 and REGN9933 are designed to help stop blood clots forming in patients with atrial fibrillation. The aim of the…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Dec 2025

Completion date move · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

ROXI-APEX: REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Phase 3RecruitingNCT07015905 ↗

Primary completion: Feb 2027; estimated
Enrollment: 2,000; estimated
Start: Jun 2025; Regeneron Pharmaceuticals

Conditions

Venous Thromboembolism (VTE)

Interventions

REGN7508
Apixaban
Enoxaparin
Placebo

Brief summary

This study is researching an experimental drug called REGN7508 (called "study drug"). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective the study drug is at preventing Venous Thromboembolism (VTE) and other related…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Aug 2025

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy

Phase 3RecruitingNCT07309432 ↗

Primary completion: Feb 2027; estimated
Enrollment: 350; estimated
Start: Jan 2026; Regeneron Pharmaceuticals

Conditions

Allergic Conjunctivitis

Interventions

REGN5713
REGN5715
Placebo

Brief summary

This study is researching 2 experimental drugs, REGN5713 and REGN5715. The study drugs will be either of these drugs given alone (either REGN5713 or REGN5715) or given together (REGN5713 and REGN5715) to reduce eye allergy signs and symptoms due to birch tree pollen allergy. The aim of the study is to see how safe…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

Phase 3RecruitingNCT06246916 ↗

Primary completion: Mar 2027; estimated
Enrollment: 560; estimated
Start: Sept 2024; Regeneron Pharmaceuticals

Conditions

Melanoma

Interventions

fianlimab
cemiplimab
relatlimab+nivolumab

Brief summary

This study is researching an experimental drug called fianlimab (also known as REGN3767), combined with another medication called cemiplimab (also known as REGN2810), called "study drugs". The study is focused on patients with a type of skin cancer known as melanoma. The aim of the study is to see how safe and…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Oct 2024

Status change · 1

Completion date move · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

AROMA: Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)

–Active, not recruitingNCT04959448 ↗

Primary completion: Mar 2027; estimated
Enrollment: 717; estimated
Start: Aug 2021; Regeneron Pharmaceuticals

Conditions

Chronic Rhinosinusitis With Nasal Polyposis

Interventions

DUPIXENT®

Brief summary

The primary objectives of the study are: * To longitudinally characterize the long-term effectiveness of DUPIXENT® through assessment of patient-reported symptoms, Health-Related Quality of Life (HRQoL) related to Chronic rhinosinusitis with nasal polyposis (CRSwNP) and other type 2 comorbidities, and their change…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

Evaluation of Cemiplimab in Combination With Platinum-Doublet Chemotherapy in First-Line (1L) Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) in Adult United States (US) Patients

–Active, not recruitingNCT06269133 ↗

Primary completion: Mar 2027; estimated
Enrollment: 1,000; estimated
Start: Feb 2024; Regeneron Pharmaceuticals

Conditions

Advanced Non-small Cell Lung Cancer

Interventions

REGN2810
Platinum-doublet chemotherapy

Brief summary

This multi-year cohort study will assess the real-world safety and effectiveness of 1L treatment with cemiplimab in combination with platinum-doublet chemotherapy across advanced NSCLC patient subgroups defined by age, sex, race, and ethnicity. Patients will be retrospectively identified from at least two US…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

AIM4:Next Step: Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Phase 4Active, not recruitingNCT06572228 ↗

Primary completion: Apr 2027; estimated
Enrollment: 120; estimated
Start: Aug 2024; Regeneron Pharmaceuticals

Conditions

Asthma

Interventions

dupilumab
Matching Placebo
ICS/LABA

Brief summary

This study is researching a drug called dupilumab. The study is focused on patients who have uncontrolled asthma. Asthma is a condition where the airways narrow and swell, making it difficult to breathe. Uncontrolled asthma means that patients are still having frequent symptoms while taking their current asthma…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jun 2026

Status change · 2

Completion date move · 1

Enrollment change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

Phase 1RecruitingNCT03564340 ↗

Primary completion: May 2027; estimated
Enrollment: 890; estimated
Start: May 2018; Regeneron Pharmaceuticals

Conditions

Recurrent Ovarian Cancer
Recurrent Fallopian Tube Cancer
Recurrent Primary Peritoneal Cancer
Recurrent Endometrial Cancer
Endometrial Cancer
Low-grade Serous Ovarian Cancer

Interventions

Ubamatamab
Cemiplimab
Sarilumab
Tocilizumab

Brief summary

The main purpose of this study is to: * Learn about the safety of ubamatamab and to find out what dose of ubamatamab can be given alone or with cemiplimab to patients with ovarian cancer or cancer of the uterus * The study will also look at the levels of ubamatamab and/or cemiplimab in the body and measure how well…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Completion date move · 3

Enrollment change · 2

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)

Phase 1RecruitingNCT06836609 ↗

Primary completion: May 2027; estimated
Enrollment: 132; estimated
Start: Apr 2025; Regeneron Pharmaceuticals

Conditions

Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic Dysfunction-Associated Steatohepatitis

Interventions

ALN-CIDEB
Placebo

Brief summary

This study is researching an experimental drug called ALN-CIDEB, also referred to as "study drug". The study is focused on participants with metabolic dysfunction-associated steatotic liver disease (MASLD) (Part A) and metabolic dysfunction-associated steatohepatitis (MASH) (Part B). MASLD and MASH are long-lasting…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Apr 2026

Enrollment change · 1

Completion date move · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

ROXI-ASPEN: REGN7508 Versus Acetylsalicylic Acid (ASA) for Venous Thromboprophylaxis After Total Knee Arthroplasty in Adult Participants

Phase 3RecruitingNCT07213778 ↗

Primary completion: May 2027; estimated
Enrollment: 2,000; estimated
Start: Nov 2025; Regeneron Pharmaceuticals

Conditions

Symptomatic Venous Thromboembolism (VTE)

Interventions

REGN7508
Acetylsalicylic Acid (ASA)
Placebo

Brief summary

This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called Acetylsalicylic Acid (ASA). The study is focused on adults undergoing elective, unilateral (one side) total knee replacement surgery. The aim of the study is to see how effective…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jan 2026

Status change · 1

Completion date move · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Phase 2RecruitingNCT06465329 ↗

Primary completion: May 2027; estimated
Enrollment: 120; estimated
Start: Nov 2024; Regeneron Pharmaceuticals

Conditions

Non-Small Cell Lung Cancer

Interventions

Cemiplimab
Platinum-based chemotherapy
REGN7075

Brief summary

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer for whom surgery is planned. The aim is to find out whether an investigational treatment (consisting of the immunotherapy drug cemiplimab plus chemotherapy plus a third drug) works better than cemiplimab plus…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Aug 2025

Completion date move · 2

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

KYRIAD: A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea

Phase 2RecruitingNCT07235917 ↗

Primary completion: Aug 2027; estimated
Enrollment: 34; estimated
Start: Mar 2026; Regeneron Pharmaceuticals

Conditions

Functional Hypothalamic Amenorrhea (FHA)

Interventions

Mibavademab
Placebo

Brief summary

This study is researching an experimental drug called mibavademab (also called "study drug"). The study is focused on patients with a condition called Functional Hypothalamic Amenorrhea (FHA). FHA is a condition where a woman stops menstruating because the brain is not sending the correct hormonal signals to the…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Mar 2026

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Phase 1Active, not recruitingNCT06369467 ↗

Primary completion: Aug 2027; estimated
Enrollment: 6; estimated
Start: May 2024; Regeneron Pharmaceuticals

Conditions

Food Allergy

Interventions

linvoseltamab
dupilumab

Brief summary

This study is researching an experimental drug called linvoseltamab combined with another drug called dupilumab. The study is looking at patients who have severe IgE-mediated food allergy. If the patient has an allergy, the body's defense system (immune system) overreacts to an allergen (eg, certain foods like…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Jul 2025

Completion date move · 2

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

ANCHOR-POC: Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Phase 2RecruitingNCT07271186 ↗

Primary completion: Sept 2027; estimated
Enrollment: 270; estimated
Start: Jan 2026; Regeneron Pharmaceuticals

Conditions

Diabetic Kidney Disease (DKD)

Interventions

ALN-ANG3
Evinacumab
ALN-ANG3 placebo
Evinacumab placebo

Brief summary

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: *…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Mar 2026

Status change · 1

Completion date move · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2Active, not recruitingNCT05785767 ↗

Primary completion: Sept 2027; estimated
Enrollment: 149; estimated
Start: Jun 2023; Regeneron Pharmaceuticals

Conditions

Advanced Non-Small Cell Lung Cancer

Interventions

fianlimab
cemiplimab
Placebo

Brief summary

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab (also called REGN2810), individually called a "study drug" or collectively called "study drugs". The study is focused on patients who have advanced non-small cell lung cancer…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Feb 2026

Completion date move · 3

Status change · 2

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy

Phase 3Not yet recruitingNCT07675811 ↗

Primary completion: Oct 2027; estimated
Enrollment: 570; estimated
Start: Jul 2026; Regeneron Pharmaceuticals

Conditions

Allergic Conjunctivitis

Interventions

REGN-2Cat
Freneslerbart
Mevonlerbart
Placebo

Brief summary

This study is researching two experimental medicines, freneslerbart and mevonlerbart. Freneslerbart and mevonlerbart can be given alone or together. When given together, the medicine is called "REGN-2Cat". These medicines are also known as the "study drugs". The aim of the study is to see what side effects…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

Phase 1RecruitingNCT03972657 ↗

Primary completion: Nov 2027; estimated
Enrollment: 345; estimated
Start: Aug 2019; Regeneron Pharmaceuticals

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clear Cell Renal Cell Carcinoma (ccRCC)

Interventions

REGN5678
Cemiplimab

Brief summary

The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug\[s\]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab. The study has 2 parts. The goal of Part 1 (dose escalation) is to determine a safe dose(s)…

Full record on ClinicalTrials.gov ↗

Change timeline

6 recorded · latest 1 Nov 2025

Completion date move · 3

Enrollment change · 3

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)

Phase 1Active, not recruitingNCT05092347 ↗

Primary completion: Nov 2027; estimated
Enrollment: 43; estimated
Start: Aug 2022; Regeneron Pharmaceuticals

Conditions

Chronic Kidney Disease (CKD)

Interventions

Vonsetamig

Brief summary

The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation. Vonsetamig is being studied for treatment of patients in need of kidney transplantation who are highly sensitized to HLA. The study is looking at several other research…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 May 2026

Completion date move · 3

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

SIENNA: A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Phase 3RecruitingNCT06541704 ↗

Primary completion: Nov 2027; estimated
Enrollment: 975; estimated
Start: Oct 2024; Regeneron Pharmaceuticals

Conditions

Age-related Macular Degeneration (AMD)
Geographic Atrophy (GA)

Interventions

Pozelimab
Cemdisiran
Placebo

Brief summary

This study is researching experimental (study) drugs called pozelimab and cemdisiran. The study is focused on participants who have Geographic Atrophy (GA) caused by Age-related Macular Degeneration (AMD). Geographic atrophy is a medical term that refers to later-stage cases of AMD which is an eye condition affecting…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Aug 2025

Enrollment change · 1

Completion date move · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

OLYMPIA-1: A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

Phase 3RecruitingNCT06091254 ↗

Primary completion: Feb 2028; estimated
Enrollment: 822; estimated
Start: Dec 2023; Regeneron Pharmaceuticals

Conditions

Follicular Lymphoma (FL)

Interventions

Odronextamab
Rituximab
Cyclophosphamide
Doxorubicin
Vincristine
Prednisone/prednisolone
Bendamustine

Brief summary

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on participants with previously untreated follicular lymphoma (a type of non-Hodgkin lymphoma or NHL). This study will be made up of two parts: Part 1 (non-randomized) and Part 2 (randomized -…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Apr 2026

Enrollment change · 2

Status change · 2

Completion date move · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

ILLUMINATE: Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH)

Phase 2RecruitingNCT07318597 ↗

Primary completion: Feb 2028; estimated
Enrollment: 99; estimated
Start: May 2026; Regeneron Pharmaceuticals

Conditions

Pulmonary Arterial Hypertension (PAH)

Interventions

REGN13335
Placebo

Brief summary

This study is researching an experimental drug called REGN13335. The study is focused on participants with Pulmonary Arterial Hypertension (PAH). The aim of the study is to see how safe and effective REGN13335 is in participants with PAH who are taking other PAH medicines. The study is looking at several other…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 May 2026

Status change · 1

Completion date move · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1RecruitingNCT05137054 ↗

Primary completion: Mar 2028; estimated
Enrollment: 317; estimated
Start: Aug 2022; Regeneron Pharmaceuticals

Conditions

Multiple Myeloma

Interventions

Linvoseltamab
Daratumumab
Carfilzomib
Lenalidomide
Bortezomib
Pomalidomide
Isatuximab
Fianlimab

Brief summary

This study is researching an experimental drug called linvoseltamab in combination with other drugs for the treatment of a blood cancer called multiple myeloma. Linvoseltamab has previously been studied as a single agent (without other cancer treatments) in participants with multiple myeloma that returned after prior…

Full record on ClinicalTrials.gov ↗

Change timeline

8 recorded · latest 1 Jul 2025

Completion date move · 6

Enrollment change · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

OLYMPIA-3: A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Phase 3RecruitingNCT06091865 ↗

Primary completion: Mar 2028; estimated
Enrollment: 904; estimated
Start: Dec 2023; Regeneron Pharmaceuticals

Conditions

Diffuse Large B-cell Lymphoma (DLBCL)

Interventions

Odronextamab
Rituximab
Cyclophosphamide
Doxorubicin
Vincristine
Prednisone/Prednisolone

Brief summary

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treated before (called "previously untreated"). Patients with DLBCL that have come…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Status change · 2

Completion date move · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

NASHGEN-2: A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

Phase 2RecruitingNCT05519475 ↗

Primary completion: Apr 2028; estimated
Enrollment: 120; estimated
Start: Feb 2023; Regeneron Pharmaceuticals

Conditions

Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

Interventions

ALN-HSD
Placebo

Brief summary

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have Metabolic dysfunction-Associated SteatoHepatitis (MASH). MASH is a form of Metabolic dysfunction-Associated Steatotic Liver Disease (MASLD). MASH occurs when fat builds up in…

Full record on ClinicalTrials.gov ↗

Change timeline

9 recorded · latest 1 May 2026

Enrollment change · 3

Completion date move · 3

Status change · 3

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

LAGO: Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy

Phase 3RecruitingNCT07220785 ↗

Primary completion: May 2028; estimated
Enrollment: 28; estimated
Start: Mar 2026; Regeneron Pharmaceuticals

Conditions

Generalized Lipodystrophy

Interventions

Mibavademab
Placebo

Brief summary

This study is researching a new drug called mibavademab (called "study drug"). The study involves participants with a condition called Generalized Lipodystrophy (GLD). The aim of the study is to see how well mibavademab works and what side effects it has. Researchers will also look at how much mibavademab is in the…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Apr 2026

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

OLYMPIA-4: A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Phase 3Active, not recruitingNCT06230224 ↗

Primary completion: May 2028; estimated
Enrollment: 216; estimated
Start: Feb 2024; Regeneron Pharmaceuticals

Conditions

B-Cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

Odronextamab
Ifosfamide
Carboplatin
Etoposide
Rituximab
Dexamethasone
Cisplatin
Cytarabine

Brief summary

This study is researching an experimental drug called odronextamab, referred to as study drug. The study is focused on patients with previously treated aggressive B-cell non-Hodgkin lymphoma whose cancer has stopped responding to treatment (also known as 'refractory') or has returned (also known as 'relapsed'). The…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jun 2026

Completion date move · 2

Status change · 1

Enrollment change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 2RecruitingNCT06769698 ↗

Primary completion: Jun 2028; estimated
Enrollment: 120; estimated
Start: Apr 2026; Regeneron Pharmaceuticals

Conditions

Head and Neck Squamous Cell Carcinoma (HNSCC)

Interventions

FDC fianlimab+cemiplimab
Cemiplimab
Placebo

Brief summary

This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not contain any real medicine), collectively called "study drugs" in this form. The study is…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2026

Status change · 1

Completion date move · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

EoE-TOTs: A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis

Phase 3RecruitingNCT07112378 ↗

Primary completion: Jun 2028; estimated
Enrollment: 20; estimated
Start: Nov 2025; Regeneron Pharmaceuticals

Conditions

Eosinophilic Esophagitis (EoE)

Interventions

dupilumab

Brief summary

This study is researching an experimental drug called dupilumab (called "study drug"). The study is focused on children with active eosinophilic esophagitis (EoE; an inflammatory disease of the esophagus) which impacts feeding and nourishment. The aim of the study is to see how safe, tolerable, and effective the…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Apr 2026

Completion date move · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

MISSION: This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

Phase 4Not yet recruitingNCT07587658 ↗

Primary completion: Jul 2028; estimated
Enrollment: 754; estimated
Start: Jun 2026; Regeneron Pharmaceuticals

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

dupilumab
Placebo

Brief summary

This study is researching a drug called dupilumab, referred to as "study drug". The study is focused on people diagnosed with COPD to determine if the study drug, in addition to standard of care treatment for COPD, might reduce the reoccurrence of a COPD exacerbation (a "flare-up") happening within the study treatment…

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

LINKER-AL2: A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

Phase 1RecruitingNCT06292780 ↗

Primary completion: Aug 2028; estimated
Enrollment: 220; estimated
Start: Aug 2024; Regeneron Pharmaceuticals

Conditions

Relapsed/Refractory Systemic Light Chain Amyloidosis

Interventions

Linvoseltamab

Brief summary

This study is researching an experimental drug called linvoseltamab ("study drug"). This study is focused on patients who have AL amyloidosis that has returned or have failed other therapies and need to be treated again. The study consists of 2 phases (Phase 1 and Phase 2): * In Phase 1, linvoseltamab will be given…

Full record on ClinicalTrials.gov ↗

Change timeline

1 recorded · latest 1 Oct 2024

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Phase 2RecruitingNCT06787612 ↗

Primary completion: Oct 2028; estimated
Enrollment: 220; estimated
Start: May 2025; Regeneron Pharmaceuticals

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

Ubamatamab
Bevacizumab
Cemiplimab
Fianlimab
PLD
Sarilumab

Brief summary

This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on patients who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other anti-cancer drugs…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 May 2026

Completion date move · 2

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

CEMI-LUNG: An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe

–RecruitingNCT05363319 ↗

Primary completion: Oct 2028; estimated
Enrollment: 500; estimated
Start: Oct 2022; Regeneron Pharmaceuticals

Conditions

Non-small Cell Lung Cancer

Interventions

Cemiplimab
Platinum-based chemotherapy

Brief summary

This study is focused on patients with non-small cell lung cancer (NSCLC) and have been prescribed a cemiplimab (Libtayo®) based treatment regimen under standard care. The goal of this study is to learn more about the use, benefits, and safety of cemiplimab based treatment regimens in participants with NSCLC.

Full record on ClinicalTrials.gov ↗

Change timeline

No changes recorded on this trial in the observed window.

OLYMPIA-5: A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

Phase 3RecruitingNCT06149286 ↗

Primary completion: Jan 2029; estimated
Enrollment: 470; estimated
Start: Dec 2023; Regeneron Pharmaceuticals

Conditions

Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

Interventions

Odronextamab
Lenalidomide
Rituximab

Brief summary

This study is researching an experimental drug called odronextamab (referred to as study drug), in combination with lenalidomide. The study is focused on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back after treatment (called "relapsed"), or…

Full record on ClinicalTrials.gov ↗

Change timeline

2 recorded · latest 1 Oct 2024

Completion date move · 2

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

ATHENA-1: A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

Phase 1RecruitingNCT05685173 ↗

Primary completion: Feb 2029; estimated
Enrollment: 107; estimated
Start: Apr 2023; Regeneron Pharmaceuticals

Conditions

B-cell Non-Hodgkins Lymphoma (B-NHL)

Interventions

Odronextamab
REGN5837

Brief summary

This study is researching an experimental drug called REGN5837 in combination with another drug, odronextamab (called "study drug\[s\]"), in patients with relapsed or refractory aggressive B-cell Non-Hodgkin Lymphomas (B-NHLs). The study has 2 parts. The aim of the first part (dose escalation) is to find a safe dose…

Full record on ClinicalTrials.gov ↗

Change timeline

3 recorded · latest 1 Jun 2026

Completion date move · 1

Enrollment change · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

ACCESS-EXT: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works

Phase 3RecruitingNCT05744921 ↗

Primary completion: Feb 2029; estimated
Enrollment: 202; estimated
Start: Mar 2023; Regeneron Pharmaceuticals

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

Pozelimab
Cemdisiran

Brief summary

This study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdisiran combination is for people with…

Full record on ClinicalTrials.gov ↗

Change timeline

4 recorded · latest 1 Jul 2024

Completion date move · 2

Enrollment change · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab

CHORD: A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations

Phase 1RecruitingNCT05788536 ↗

Primary completion: Feb 2029; estimated
Enrollment: 36; estimated
Start: Jun 2023; Regeneron Pharmaceuticals

Conditions

Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)

Interventions

DB-OTO

Brief summary

Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat pediatric and adult participants who have severe-to profound and profound hearing loss due to changes in the otoferlin gene. The purpose of this study is to: * Learn about the…

Full record on ClinicalTrials.gov ↗

Change timeline

5 recorded · latest 1 Jun 2026

Completion date move · 3

Enrollment change · 1

Status change · 1

Track Regeneron drugs to see every change the night it lands.

Track dupilumab